PATENT CLAIM ANALYSIS

Application Number: 15888519
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["514", "007200"]

Abstract:
Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA 1c  and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

Claim (Index 13):
The method of  claim 8 , wherein the sustained minimum plasma concentration of the exendin-4 is between 200 pg/ml to 350 pg/ml.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 88.0
- Lexical Diversity: 1.27586
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13708474', '13084757', '12298933', '11272488', '11584114']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8884335230499135
- 35 USC 102 Novelty (BERT): 0.7415491587293306
- Combined Prediction Score: 0.8737450866178553
- Mean Citation Score: 849.0850300000003
- Max Citation Score: 1108.6364
- Similarity Product: 829.387986391878

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test